Webinar

Tricky Business: Rethinking Our Approach to Tackling Schizophrenia

Launch Date
06/15/2023
Credit Amount
1.0
Credit Expires
06/15/2024

Faculty

Rakesh Jain, MD, MPH
(he/him/his)
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine – Permian Basin
Midland, TX
Rakesh Jain, MD, MPH

Rakesh Jain, MD, MPH, is a Clinical Professor in the department of Psychiatry at the Texas Tech Health Sciences Center School of Medicine – Permian Basin in Midland, Texas and in private practice in Austin, Texas. Dr. Jain attended medical school at the University of Calcutta in India. He received his Master of Public Health (MPH) degree from the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on the impact of substance abuse.

Dr. Jain completed his residency in psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He then completed a postdoctoral fellowship in research psychiatry at the University of Texas Mental Sciences Institute in Houston. He was awarded the National Research Service Award in support of his postdoctoral fellowship.

Dr. Jain has been involved in over 100 research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, ADHD, and psychosis in adult and child/adolescent populations. He has presented at the World Psychiatric Congress held in Prague, and at Depression and Pain Forum meetings internationally. He is the author of 55 articles published in various journals and magazines, such as the Journal of Psychiatric Research and  Journal of Clinical Psychiatry, among others, and has presented over 25 original research posters at meetings such as the American Psychological Association (APA), the American College of Neuropsychopharmacology (ACNP), the American Academy of Child and Adolescent Psychiatry (AACAP), the U.S. Psychiatric Congress, and more. He has co-authored six books that range from patient education to cutting-edge neurobiologic findings in psychiatry and mental health. He serves on several advisory boards focusing on drug development and disease state education. He was also recently the Chair of the U.S. Psychiatric Congress, and for several years, has served as a member of the Steering Committee for U.S. Psychiatric Annual Congress. He is a recipient of the Public Citizen of the Year award from the National Association of Social Workers, Gulf Coast Chapter, in recognition of his community and peer education, and championing of mental health issues.

Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell, New York, USA
Professor and Chair, Department of Child and Adolescent Psychiatry
Charité University Medicine, Berlin, Germany
Christoph U. Correll, MD

Christoph U. Correll is a Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, and serves as Professor and Chair of the Department of Child and Adolescent Psychiatry, at Charité University Medicine, Berlin, Germany. Dr. Correll completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed two residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, and since 2017 he has been working in Germany.

Dr. Correll focuses on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health. He has authored or co-authored over 850 journal articles that have been cited more than 68.000 times and received over 40 research awards for his work. In August 2023, his H-index was 136 in Google Scholar. Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com).

Dawn I. Velligan, PhD
Professor, Department of Psychiatry
Chief, Division of Community Recovery, Research and Training
Henry B. Dielmann Chair
University of Texas Health Science Center
San Antonio, TX
Dawn I. Velligan, PhD

Dr. Dawn Velligan is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and Henry B. Dielmann Chair at the University of Texas Health Science Center at San Antonio.  Dr. Velligan’s internationally recognized research program focuses on the development and testing of psychosocial treatments to bypass cognitive and motivation problems in schizophrenia and improve medication follow through and outcomes.   She developed Cognitive Adaptation Training (CAT) a unique treatment system designed to bypass the cognitive problems observed in serious mental illness and improve functional outcomes.  Dr. Velligan has dedicated her career to developing, and delivering state-of-the-art psychosocial treatments to make lives better for those with serious mental illness. Dr. Velligan’s latest work has included the development of a multi-level program targeting administrators, providers, and individuals in treatment to facilitate shared decision making and increase the use of long-acting formulations of antipsychotic medication at the systems level.  Dr. Velligan is author of numerous publications in high impact journals on cognitive and functional impairment and adherence and she has received grant funding from the National Institute of Health, The Brain and Behavior Research Foundation, industry and private foundations.  She frequently serves as a consultant to industry and scientific investigators in the areas of symptom assessment, medication adherence and follow through, cognition and outcomes.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Current standards of care for schizophrenia, generally targeting the dopaminergic pathway, demonstrate efficacy in positive symptoms in patients, but with varied results for other symptoms. Unresolved negative symptoms, and symptoms related to cognitive impairment associated with schizophrenia (CIAS), represent unmet patient needs that may be addressed with newer therapies targeting newly proposed, non-dopaminergic pathways. Clinicians in psychiatry may benefit from understanding how deficits in current treatment options for schizophrenia and CIAS may be addressed given research related to the pathophysiology of schizophrenia and medical needs of patients.

In this recorded, CME Outfitters webcast entitled, Tricky Business: Rethinking Our Approach to Tackling Schizophrenia, a panel of expert faculty will utilize animated 3-D models to discuss pathophysiology, negative symptomology, and CIAS in schizophrenia, identify the impact of unmet patient medical needs and examine current emerging therapies in the treatment of schizophrenia.

Learning Objectives

  • Translate non-dopaminergic pathophysiology to the manifestation of cognitive impairment and negative symptoms in schizophrenia.
  • Identify the impact of disease including unmet medical needs and deficiencies associated with CIAS on patients with schizophrenia.
  • Examine current and emerging therapies for CIAS, factoring in limitations as part of management strategies.

Financial Support

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Psychiatrists and nurse practitioners (NPs), and physician associates (PAs) and pharmacists specializing in psychiatry.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
JA0007185-0000-23-076-H01-P

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Jain reports the following financial relationships:

Advisory Board: Adamas Pharmaceuticals, Inc.; Alkermes; Corium, Inc.; Eisai Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Usona Institute

Consultant: AbbVie Inc. (Allergan); Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alfasigma USA, Inc.; Axsome Therapeutics, Inc.; Biogen; Boehringer Ingleheim; Corium, Inc.; Cingulate; Eisai Inc.; Evidera; Impel Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica Pharmaceuticals; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Transcend Therapeutics

Research Support: AbbVie Inc. (Allergan); Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc. (Allergan); Alkermes; Axsome Therapeutics, Inc.; Corium, Inc.; Eisai Inc.; Indivior; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Tris Pharma, Inc.

Dr. Correll reports the following financial relationships:

Advisory Board: AbbVie Inc.; Allergan; Angelini Pharma Inc; Biogen; Compass Therapeutics, Inc.; Gedeon Richter; Janssen Pharmaceuticals, Inc./J&J; Karuna Therapeutics; Lundbeck; MedInCell; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc; Recordati; Rovi; Sage Therapeutics, Inc; Seqirus; SK Life Science, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc; Axsome Therapeutics, Inc.; Cardio Diagnostics Inc.; Cerevel Therapeutics; COMPASS Pathways; Gedeon Richter; Holmusk; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals, Inc./J&J; Karuna Therapeutics; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Medscape; Merck & Co., Inc.; Mindpax; Mylan; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Rovi; Seqirus; Servier; SK Life Science, Inc.; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Viatris Inc.

Grants and Research Support: Janssen Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.

Stock Shareholder (ownership interest): Cardio Diagnostics Inc.; Mindpax; LB Pharma; PsiloSterics; and Quantic (Options)

Dr. Velligan reports the following financial relationships:

Advisory Board and Consultant: Alkermes; Boehringer Ingelheim; Janssen Pharmaceuticals, Inc.; Karuna Therapeutics; Otsuka America Pharmaceutical, Inc.; and Teva Pharmaceuticals USA, Inc.

Speakers Bureau: Janssen Pharmaceuticals, Inc. and Otsuka America Pharmaceutical, Inc.

 

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Christina Rivera Carpenter, PhD, RN (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-072-061523-25

Tricky Business: Rethinking Our Approach to Tackling Schizophrenia
Event Date: 06/15/2023
Register

Related Activities